Financial Results
Starsource Multitrade Publishes Q2 Results
Starsource Multitrade published newspaper advertisements containing unaudited financial results for the quarter ended September 30, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
4
Neutral
5
Bullish
5
Bearish
19
Neutral
5
Bullish
22
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Pharmaceuticals & Biotechnology
Pharmaceuticals
16 Cr
Low Risk
-79.9
39.5
—
12.8
152.90
70.01
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Financial Results
Starsource Multitrade published newspaper advertisements containing unaudited financial results for the quarter ended September 30, 2026.
Financial Results
Starsource Multitrade approved unaudited standalone Q2 FY27 results, reporting nil revenue and a qualified limited review conclusion related to GST compliance.
Starsource Multitrade Ltd (CHEMOPH) is currently trading at 106.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Starsource Multitrade Limited (formerly Chemo Pharma Laboratories Limited) is a small publicly listed company established in 1942 that exited active pharmaceutical manufacturing and now positions itself as a trading and investment vehicle pursuing acquisitions and diversification into Power and Chemicals, supported by existing cash resources and a recent corporate name change effected in August 2025. Financials for FY2026 show total standalone income of Rs. 5,495 thousand and a very large other expense line of Rs. 119,377 thousand, producing a standalone net loss of Rs. 118,549.73 thousand; cash balances declined from about Rs. 106,228 thousand at the start of year to Rs. 122.26 thousand at year end, evidencing material cash depletion during FY2026. The statutory auditor issued an unmodified opinion on the FY2026 audited results, but the auditor’s report flagged significant disclosure and control weaknesses: GST-reported turnover mismatch with books, lack of balance confirmations, and unsupported fair value loss entries, raising governance and financial reporting risk despite the clean audit opinion. Company management declares active pursuit of a takeover/rehabilitation of a sick company in Power and Chemicals and plans to redeploy cash resources into that acquisition, representing a strategic pivot from legacy pharmaceutical activity toward capital-intensive industrial sectors and M&A-driven growth. Operationally the company currently reports no product brands or active business segments, with notes saying there are no reportable segments; the near-term business case therefore depends on successful completion and integration of announced acquisitions and resolution of current financial reporting discrepancies.
Over the past 52 weeks, Starsource Multitrade Ltd has traded between a low of ₹70.01 and a high of ₹152.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Starsource Multitrade Ltd has a market capitalization of approximately 15.98. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Starsource Multitrade Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -79.90 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 15.98 Cr, Starsource Multitrade Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Starsource Multitrade Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Starsource Multitrade Ltd is -79.90. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Starsource reported nil revenue from operations for the quarter ended September 30, 2026. Revenue was Rs 7.46 lakh in the June 2026 quarter and Rs 52.57 lakh in the September 2025 quarter. Other income was also nil in the latest quarter.
Starsource Multitrade reported net profit of ₹0.02 crore for the quarter ended June 30, 2026. The result followed a net loss in the corresponding quarter of the previous year.